EP Patent

EP3368097B1 — Apparatus and methods for dispensing oral transmucosal dosage forms

Assigned to Talphera Inc · Expires 2020-03-18 · 6y expired

What this patent protects

Patent listed against sufentanil-citrate.

Drugs covered by this patent

sufentanil-citrate (SUFENTANIL CITRATE)

Patent Metadata

Patent number: EP3368097B1
Jurisdiction: EP
Classification: —
Expires: 2020-03-18
Drug substance claim: No
Drug product claim: No
Assignee: Talphera Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.